New targets and approaches are under investigation for the treatment of nonmuscle invasive bladder cancer (NMIBC). Preclinical data suggest cyclooxygenase-2 (COX-2) as a promising target. Celecoxib, a COX-2 selective inhibitor, inhibits tumor development and enhances survival, both in vitro and in vivo models of bladder cancer. Therefore, we conducted a pilot study of celecoxib to prevent recurrence in patients with intermediate risk NMIBC.

Pagliarulo, V., Ancona, P., Martines, I., Spadavecchia, R., DI STASI, S.m., Alba, S., et al. (2015). Celecoxib for the prevention of nonmuscle invasive bladder cancer: Results from a matched control study. THERAPEUTIC ADVANCES IN UROLOGY, 7(6), 303-311 [10.1177/1756287215599695].

Celecoxib for the prevention of nonmuscle invasive bladder cancer: Results from a matched control study

DI STASI, SAVINO MAURO;
2015-12-01

Abstract

New targets and approaches are under investigation for the treatment of nonmuscle invasive bladder cancer (NMIBC). Preclinical data suggest cyclooxygenase-2 (COX-2) as a promising target. Celecoxib, a COX-2 selective inhibitor, inhibits tumor development and enhances survival, both in vitro and in vivo models of bladder cancer. Therefore, we conducted a pilot study of celecoxib to prevent recurrence in patients with intermediate risk NMIBC.
1-dic-2015
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/24 - UROLOGIA
English
Con Impact Factor ISI
bladder cancer; celecoxib; cyclooxygenase; recurrence; treatment
Pagliarulo, V., Ancona, P., Martines, I., Spadavecchia, R., DI STASI, S.m., Alba, S., et al. (2015). Celecoxib for the prevention of nonmuscle invasive bladder cancer: Results from a matched control study. THERAPEUTIC ADVANCES IN UROLOGY, 7(6), 303-311 [10.1177/1756287215599695].
Pagliarulo, V; Ancona, P; Martines, I; Spadavecchia, R; DI STASI, Sm; Alba, S; Cormio, L; Fanizza, C; Salerno, A; Carrieri, G; Pagliarulo, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
THER ADV UROL 2015 (1).pdf

accesso aperto

Licenza: Non specificato
Dimensione 504.57 kB
Formato Adobe PDF
504.57 kB Adobe PDF Visualizza/Apri
THER ADV UROL 2015 (1).pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 504.57 kB
Formato Adobe PDF
504.57 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/164133
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact